ppt冠心病合并慢性肾脏疾病的介入治疗进展.pptVIP

冠心病合并慢性肾脏疾病的 介入治疗进展 ;;普通人群与肾衰患者心血管死亡率的比较; ;;CHD合并CKD的临床特点;CHD合并CKD的PCI疗效;;CHD合并CKD的PCI治疗存在问题;;One-year Kaplan-Meier survival curves stratified by CrCl levels ;;;Mehran评分的高低可部分预测对比剂急性肾损伤(AKI)发生率的高低;;;CHD合并CKD的PCI治疗适应症选择;;CHD合并CKD冠脉病变特点和PCI技术难点;;;CHD合并CKD的PCI围手术期注意事项;;NEPHRIC研究方法;NEPHRIC入选和排除标准;NEPHRIC实验流程;NEPHRIC主要终点;Differences in Nephrotoxicity between Iodixanol and IohexolThe bars show the numbers of patients with a maximal increase in the serum creatinine concentration between day 0 and day 3 of at least 0.5 mg per deciliter and at least 1.0 mg per deciliter, which are the two most commo